Increased Baseline Proinflammatory Cytokine Production in Chronic Hepatitis C Patients with Rapid Virological Response to Peginterferon Plus Ribavirin

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Par, Gabriella ^a   Szereday, Laszlo ^a   Berki, Timea ^a   Palinkas, Laszlo ^a   Halasz, Melinda ^a   Miseta, Attila ^b   Hegedus, Geza ^c   Szekeres Bartho, Julia ^a   Vincze, Aron ^a   Hunyady, Bela ^a   Par, Alajos ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Baranya County Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IONOMYCIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHORBOL 13 ACETATE 12 MYRISTATE; RIBAVIRIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LYMPHOCYTE; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; TH1 CELL; TH2 CELL;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; RIBAVIRIN; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84879936187     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067770     Document Type: Article

References (51)

1. Spengler U, Nattermann J (2007) Immunopathogenesis in hepatitis C virus cirrhosis. Clinical science 112: 141-155. Available: http://www.ncbi.nlm.nih.gov/pubmed/17199558. Accessed 21 September 2011.
2. Lloyd AR, Jagger E, Post JJ, Crooks L-A, Rawlinson WD, et al. (2007) Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunology and cell biology 85: 24-32. Available: http://www.ncbi.nlm.nih.gov/pubmed/17130897. Accessed 21 September 2011.
3. Rehermann B (2009) Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. The Journal of clinical investigation 119: 1745-1754. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2701885&tool=pmcentrez&rendertype=abstract. Accessed 26 June 2012.
4. Burke KP, Cox AL (2010) Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunologic research 47: 216-227. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2910517&tool=pmcentrez&rendertype=abstract. Accessed 26 June 2012.
5. Ciuffreda D, Kim AY (2011) Update on hepatitis C virus-specific immunity. Current opinion in HIV and AIDS 6: 559-565. Available: http://www.ncbi.nlm.nih.gov/pubmed/22001897. Accessed 26 June 2012.
6. Neumann-Haefelin C, Thimme R (2011) Success and failure of virus-specific T cell responses in hepatitis C virus infection. Digestive diseases (Basel, Switzerland) 29: 416-422. Available: http://www.ncbi.nlm.nih.gov/pubmed/21894013. Accessed 26 June 2012.
7. Pár G, Rukavina D, Podack ER, Horányi M, Szekeres-Barthó J, et al. (2002) Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. Journal of hepatology 37: 514-522. Available: http://www.ncbi.nlm.nih.gov/pubmed/12217606. Accessed 9 May 2011.
8. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna K V, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401. Available: http://www.ncbi.nlm.nih.gov/pubmed/19684573. Accessed 1 March 2012.
9. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics 41: 1100-1104. Available: http://www.ncbi.nlm.nih.gov/pubmed/19749758. Accessed 2 March 2012.
10. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, et al. (2010) A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139: 1586-92, 1592.e1. Available: http://www.ncbi.nlm.nih.gov/pubmed/20637200. Accessed 26 June 2012.
11. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-9.e18. Available: http://www.ncbi.nlm.nih.gov/pubmed/20399780. Accessed 27 March 2012.
12. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America 105: 7034-7039. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2383932&tool=pmcentrez&rendertype=abstract. Accessed 18 June 2012.
13. Mogensen TH (2009) Pathogen recognition and inflammatory signaling in innate immune defenses. Clinical microbiology reviews 22: 240-73. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2668232&tool=pmcentrez&rendertype=abstract. Accessed 5 July 2011.
14. Clark V, Nelson DR (2012) The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver international: official journal of the International Association for the Study of the Liver 32 Suppl 1: 103-107. Available: http://www.ncbi.nlm.nih.gov/pubmed/22212579. Accessed 3 March 2012.
15. Kondo Y, Ueno Y, Wakui Y, Ninomiya M, Kakazu E, et al. (2011) Rapid reduction of hepatitis C virus-Core protein in the peripheral blood improve the immunological response in chronic hepatitis C patients. Hepatology research: the official journal of the Japan Society of Hepatology 41: 1153-1168. Available: http://www.ncbi.nlm.nih.gov/pubmed/21951312. Accessed 26 June 2012.
16. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, et al. (2011) Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PloS one 6: e27866. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3218071&tool=pmcentrez&rendertype=abstract. Accessed 20 April 2012.
17. Atsukawa M, Nakatsuka K, Kobayashi T, Shimizu M, Tamura H, et al. (2012) Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. Journal of gastroenterology and hepatology 27: 823-831. Available: http://www.ncbi.nlm.nih.gov/pubmed/21871023. Accessed 3 July 2012.
18. Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, et al. (2011) Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. The Journal of infectious diseases 203: 1087-1095. Available: http://www.ncbi.nlm.nih.gov/pubmed/21398397. Accessed 14 June 2012.
19. Umemura T, Joshita S, Yoneda S, Katsuyama Y, Ichijo T, et al. (2011) Serum interleukin (IL)-10 and IL-12 levels and IL28B gene polymorphisms: pretreatment prediction of treatment failure in chronic hepatitis C. Antiviral therapy 16: 1073-1080. Available: http://www.ncbi.nlm.nih.gov/pubmed/22024523. Accessed 26 June 2012.
20. Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, et al. (2010) Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (Baltimore, Md) 51: 1523-1530. Available: http://www.ncbi.nlm.nih.gov/pubmed/20186843. Accessed 26 June 2012.
21. Hedayat M, Netea MG, Rezaei N (2011) Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. The Lancet infectious diseases 11: 702-712. Available: http://www.ncbi.nlm.nih.gov/pubmed/21719349. Accessed 23 August 2011.
22. Schwabe RF, Seki E, Brenner DA (2006) Toll-like receptor signaling in the liver. Gastroenterology 130: 1886-1900. Available: http://www.ncbi.nlm.nih.gov/pubmed/16697751. Accessed 6 February 2012.
23. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, et al. (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43: 954-960. Available: http://www.ncbi.nlm.nih.gov/pubmed/16628671. Accessed 11 July 2011.
24. Ghany M, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the american association for the study of liver diseases. Hepatology 54: 1433-1444. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3229841&tool=pmcentrez&rendertype=abstract. Accessed 6 September 2011.
25. Tang KH, Herrmann E, Cooksley H, Tatman N, Chokshi S, et al. (2005) Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Journal of hepatology 43: 776-782. Available: http://www.ncbi.nlm.nih.gov/pubmed/16139918. Accessed 25 February 2012.
26. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, et al. (2011) IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Alimentary pharmacology & therapeutics 33: 1162-1172. Available: http://www.ncbi.nlm.nih.gov/pubmed/21443535. Accessed 20 June 2012.
27. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, et al. (2002) HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World journal of gastroenterology 8: 562-566. Available: http://www.ncbi.nlm.nih.gov/pubmed/12046093. Accessed 25 February 2012.
28. Töx U, Schulte S, Heindl B, Goeser T, Drebber U,et al. (n.d.) Ribavirin priming in patients with chronic hepatitis C and normal ALT: a pilot study. Hepato-gastroenterology 55: 1666-1670. Available: http://www.ncbi.nlm.nih.gov/pubmed/19102366. Accessed 26 June 2012.
29. Hammond T, Lee S, Watson MW, Flexman JP, Cheng W, et al. (2011) Decreased IFNγ production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy. Journal of viral hepatitis 18: 482-492. Available: http://www.ncbi.nlm.nih.gov/pubmed/20529204. Accessed 26 March 2012.
30. Hammond T, Lee S, Watson MW, Flexman JP, Cheng W, et al. (2010) Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus. Cellular immunology 264: 150-155. Available: http://www.ncbi.nlm.nih.gov/pubmed/20579979. Accessed 3 March 2012.
31. Kaukinen P, Sillanpää M, Kotenko S, Lin R, Hiscott J, et al. (2006) Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virology journal 3: 66. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1569370&tool=pmcentrez&rendertype=abstract. Accessed 25 February 2012.
32. Foy E, Li K, Sumpter R, Loo Y-M, Johnson CL, et al. (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proceedings of the National Academy of Sciences of the United States of America 102: 2986-2991. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549461&tool=pmcentrez&rendertype=abstract. Accessed 25 February 2012.
33. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, et al. (2007) Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. Journal of virology 81: 8953-8966. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1951400&tool=pmcentrez&rendertype=abstract. Accessed 17 August 2011.
34. Riordan SM, Skinner NA, Kurtovic J, Locarnini S, McIver CJ, et al. (2006) Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflammation research 55: 279-285. Available: http://www.ncbi.nlm.nih.gov/pubmed/16955390. Accessed 20 February 2012.
35. He Q, Graham CS, Durante Mangoni E, Koziel MJ (2006) Differential expression of toll-like receptor mRNA in treatment non-responders and sustained virologic responders at baseline in patients with chronic hepatitis C. Liver international 26: 1100-1110. Available: http://www.ncbi.nlm.nih.gov/pubmed/17032411. Accessed 25 February 2012.
36. Dolganiuc A, Garcia C, Kodys K, Szabo G (2006) Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection. World journal of gastroenterology 12: 1198-1204. Available: http://www.ncbi.nlm.nih.gov/pubmed/16534871. Accessed 25 February 2012.
37. Sirén J, Pirhonen J, Julkunen I, Matikainen S (2005) IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. Journal of immunology 174: 1932-1937. Available: http://www.ncbi.nlm.nih.gov/pubmed/15699120. Accessed 1 July 2011.
38. Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, et al. (2012) Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PloS one 7: e32028. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3283684&tool=pmcentrez&rendertype=abstract. Accessed 26 June 2012.
39. Li K, Li NL, Wei D, Pfeffer SR, Fan M, et al. (2012) Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology (Baltimore, Md) 55: 666-675. Available: http://www.ncbi.nlm.nih.gov/pubmed/22030901. Accessed 6 April 2012.
40. Binder M, Kochs G, Bartenschlager R, Lohmann V (2007) Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy. Hepatology 46: 1365-1374. Available: http://www.ncbi.nlm.nih.gov/pubmed/17668876. Accessed 11 July 2011.
41. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972. Available: http://www.ncbi.nlm.nih.gov/pubmed/16107837. Accessed 29 July 2011.
42. Agaugué S, Perrin-Cocon L, André P, Lotteau V (2007) Hepatitis C lipo-Viro-particle from chronically infected patients interferes with TLR4 signaling in dendritic cell. PloS one 2: e330. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1828622&tool=pmcentrez&rendertype=abstract. Accessed 3 February 2012.
43. Lau DT-Y, Fish PM, Sinha M, Owen DM, Lemon SM, et al. (2008) Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients. Hepatology (Baltimore, Md) 47: 799-809. Available: http://www.ncbi.nlm.nih.gov/pubmed/18203148. Accessed 20 April 2012.
44. Sarikonda G, Von Herrath MG (2011) Immunosuppressive mechanisms during viral infectious diseases. Methods in molecular biology (Clifton, NJ) 677: 431-447. Available: http://www.ncbi.nlm.nih.gov/pubmed/20941625. Accessed 3 July 2012.
45. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, et al. (2006) Interleukin-10 determines viral clearance or persistence in vivo. Nature medicine 12: 1301-1309. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2535582&tool=pmcentrez&rendertype=abstract. Accessed 29 June 2011.
46. Blackburn SD, Wherry EJ (2007) IL-10, T cell exhaustion and viral persistence. Trends in microbiology 15: 143-146. Available: http://www.ncbi.nlm.nih.gov/pubmed/17336072. Accessed 25 February 2012.
47. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, et al. (2006) Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Annals of clinical and laboratory science 36: 144-150. Available: http://www.ncbi.nlm.nih.gov/pubmed/16682509. Accessed 25 February 2012.
48. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, et al. (1997) Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. Journal of gastroenterology 32: 211-215. Available: http://www.ncbi.nlm.nih.gov/pubmed/9085170. Accessed 25 February 2012.
49. Ng V, Saab S (2011) Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 9: 923-930. Available: http://www.ncbi.nlm.nih.gov/pubmed/21699815. Accessed 1 March 2012.
50. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, et al. (2011) Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology (Baltimore, Md) 54: 1547-1558. Available: http://www.ncbi.nlm.nih.gov/pubmed/22045672. Accessed 26 June 2012.
51. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, et al. (2011) The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clinical pharmacology and therapeutics 89: 821-829. Available: http://www.ncbi.nlm.nih.gov/pubmed/21451504. Accessed 7 April 2012.